Comparison of optic nerve perfusion after pan retinal photocoagulation (PRP) versus anti vascular endothelial growth factor (antiVEGF) injection for treatment of high risk proliferative diabetic retinopathy(PDR)

Comparison of optic nerve perfusion after pan retinal photocoagulation (PRP) versus anti vascular endothelial growth factor (antiVEGF) injection for treatment of high risk proliferative diabetic retinopathy (PDR)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202206535473146

Enrollment

Registered

2022-06-21

Start date

2019-07-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases Paediatrics

Interventions

intravitreal anti VEGF Ranizumab

panretinal photocoagulation PRP

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Naive high risk PDR (neovascularization on disc (NVD) more than 1/3 disc area or any NVD with vitreous hemorrhage) ? clear media

Exclusion criteria

Exclusion criteria: ? patients with media opacity ? other retinal and optic nerve diseases rather than diabetic retinopathy ? anti VEGF or steroid intravitreal injection ? previous PRP ? tractional retinal detachment ? glaucoma or any form of optic neuropathy

Design outcomes

Primary

Measure	Time frame
comparing peri papillary vascular density after PRP and anti VEGF (Ranizumab)	—

Secondary

Measure	Time frame
1. Visual field change (mean deviation and pattern standard deviation) 2. macular capillary density 3. visual acuity 4. Neovascular area on disc (NVD area) if possible	—

Countries

Egypt

Contacts

Public ContactHesham Mohamed

teacher of ophthalmology faculty of medicine Ain Shams university

h_gharieb@med.asu.edu.eg01000673215

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026